Basic Information
| Drug ID | DDPD00218 |
|
| Drug Name | Moxifloxacin | |
| Molecular Weight | 401.4314 | |
| Molecular Formula | C21H24FN3O4 | |
| CAS Number | 151096-09-2 | |
| SMILES | [H][C@]12CN(C[C@@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O | |
| External Links | ||
| DRUGBANK | DB00218 | |
| PubChem Compound | 152946 | |
| PDR | 2486 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 2.9 | - | 2.9 | - | DRUGBANK |
| Melting Point | 240.0 | ℃ | 238-242 | ℃ | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 90.0 | % | ~90 | % | PO, oral; food; | food → ; | DRUGBANK | Bioavailability | 86.0 | % | 86±1 | % | PO, oral; Male, men; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| C Max | 2500.0 | ng/ml | 2.5±1.3 | mcg/ml | Oral single dose; Male, men; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | |
| T Max | 2.0 | h | 2.0(0.5-6.0) | h | Oral single dose; Male, men; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | |
| Metabolic | 52.0 | % | 52 | % | PO, oral; intravenous injection, IV; | DRUGBANK | Metabolic | 38.0 | % | 38 | % | PO, oral; intravenous injection, IV; | DRUGBANK | Metabolic | 14.0 | % | 14 | % | PO, oral; intravenous injection, IV; | DRUGBANK |
| Clearance | 12.0 | L/h | 12±2 | L/h | DRUGBANK | Clearance | 0.14 | L/h/kg | 2.27±0.24 | ml/min/kg | normal,healthy; adults; Male, men; metabolism of ugt; hydrolysis; | The Pharmacological Basis of Therapeutics | Clearance | 0.14 | L/h/kg | 2.4 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 2.2 | L/kg | 1.7-2.7 | L/kg | DRUGBANK | Volume of Distribution | 2.1 | L/kg | 2.05±1.15 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.4 | L/kg | 1.4 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 13.6 | h | 11.5-15.6 | h | Oral single dose; | DRUGBANK | Half-life | 15.4 | h | 15.4±1.2 | h | normal,healthy; adults; Male, men; | The Pharmacological Basis of Therapeutics | Half-life | 8.2 | h | 8.2 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LDLo | 100.0 | mg/kg | 100.0 | mg/kg | intravenous injection, IV; mouse; Rattus, Rat; | DRUGBANK | |
| Eliminate Route | 20.0 | % | ~20 | % | Urinary excretion; PO, oral; intravenous injection, IV; Unchanged drug; | DRUGBANK | Eliminate Route | 25.0 | % | ~25 | % | Faeces excretion; PO, oral; intravenous injection, IV; Unchanged drug; | DRUGBANK | Eliminate Route | 21.9 | % | 21.9±3.6 | % | Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 50.0 | % | 50 | % | Plasma Concentration → ; | DRUGBANK | Protein Binding | 39.4 | % | 39.4±2.4 | % | adults; Male, men; normal,healthy; human, homo sapiens; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 3.0 | drop/day | 3 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for infants | 3.0 | drop/day | 3 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for infants | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for infants | 3.0 | drop/day | 3 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for children | 3.0 | drop/day | 3 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for children | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for adolescents | 3.0 | drop/day | 3 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for adolescents | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for adults | 400.0 | mg/day | 400 | mg/day | PO, oral;intravenous injection, IV; | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for adults | 3.0 | drop/day | 3 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for adults | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for geriatric | 400.0 | mg/day | 400 | mg/day | PO, oral;intravenous injection, IV; | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for geriatric | 3.0 | drop/day | 3 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
| Max dose for geriatric | 2.0 | drop/day | 2 | drop/day | ophthalmic administration | Vigamox | moxifloxacin hydrochloride | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1